Skip to site menu Skip to page content

Menu

Search

Sections

Home
News
Analysis
Pharma
Themes
Insights
Companies
Webinar & Events
Buy Reports
Excellence Awards
Innovation Rankings
Magazine
Newsletters

GlobalData

About us
Advertise With Us
Contact Us
Our Marketing Solutions
GlobalData Reports
Visit GlobalData

From Our Partners

Biopharma Playbooks: Solutions at the Speed of Science
Simplifying clinical data processes
Control and confidence in clinical data management
Optimizing Cell & Gene Therapy Processes
Accelerating Biopharmaceutical Innovation
Precision medicine and digital health innovation for disease diagnosis, care and treatment
The next chapter of clinical trial services
Putting quality first in the pharma supply chain
Pharmaceutical Grade Silicone Manufacturer

News
Analysis
Sections
Latest
Pharma
Sections
Latest
Themes
Sections
Latest
Insights
Sections
Latest
Companies
Sections
Latest
Webinar & Events
Sections
Latest
Buy Reports
Newsletters

Analysis

Left

Right

Features
Comment & Opinion
Projects
Data Insights

Data Insights

Filter search results

By Company Name

No Filter Selected

By Disease Name

No Filter Selected

By Drug Name

No Filter Selected

By Themes

No Filter Selected

Showing 6 results out of 6

Industry Themes and Signals

Decode the future of Pharmaceuticals. Access unrivalled intelligence on new technologies, macroeconomic shifts and social trends.

Get the insights you need to stay one step ahead - from smart cities to artificial intelligence, from nanomedicine to de-globalization.
Or go granular and access the latest signals on deals, filings, patents, hiring activities and more!

Data Insights

UCART-22 by Cellectis for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval

UCART-22 is under clinical development by Cellectis and currently in Phase II for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic...

Likelihood of Approval and Phase Transition Success Rate Model - UCART-22 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)

Data Insights

UCART20x22 by Cellectis for Follicular Lymphoma: Likelihood of Approval

UCART20x22 is under clinical development by Cellectis and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - UCART20x22 in Follicular Lymphoma

Data Insights

UCART20x22 by Cellectis for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval

UCART20x22 is under clinical development by Cellectis and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - UCART20x22 in Primary Mediastinal B-Cell Lymphoma

Data Insights

UCART20x22 by Cellectis for Marginal Zone B-cell Lymphoma: Likelihood of Approval

UCART20x22 is under clinical development by Cellectis and currently in Phase II for Marginal Zone B-cell Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - UCART20x22 in Marginal Zone B-cell Lymphoma

Data Insights

UCART20x22 by Cellectis for Mantle Cell Lymphoma: Likelihood of Approval

UCART20x22 is under clinical development by Cellectis and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - UCART20x22 in Mantle Cell Lymphoma

Data Insights

Risk adjusted net present value: What is the current valuation of Cellectis's UCART-22?

UCART-22 is a gene-modified cell therapy commercialized by Cellectis, with a leading Phase II program in B-Cell Acute Lymphocytic Leukemia...

Net Present Value Model: Cellectis SA's UCART-22

The leading site for news and procurement in the pharmaceutical industry

About us
Advertise with us
License our content
Contact us
Editorial approach
Newsletters
Our marketing solutions

Privacy policy
Terms and conditions
Sitemap

Powered by

© GlobalData Plc 2026

Lost Password Back ⟶
Login
Register

Lost Password?

Registration is disabled.